Tumor residue in patients with stage II–IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein–Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose

Tumor residue in patients with stage II–IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein–Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose

Abstract Background To develop and validate a predictive nomogram for tumor residue 3–6 months after treatment based on postradiotherapy plasma Epstein–Barr virus (EBV) deoxyribonucleic acid (DNA), clinical stage, and radiotherapy (RT) dose in patients with stage II–IVA nasopharyngeal carcinoma (NPC...

Full description

Bibliographic Details
Main Authors: Ying-Ying Huang, Jia-Yu Zhou, Ze-Jiang Zhan, Liang-Ru Ke, Wei-Xiong Xia, Xun Cao, Zhuo-Chen Cai, Ying Deng, Xi Chen, Lu-Lu Zhang, Hao-Yang Huang, Xiang Guo, Xing Lv
Format: Article
Language:English
Published: BMC 2023-05-01
Series:BMC Cancer
Subjects:
Nasopharyngeal carcinoma
Intensity-modulated radiotherapy
Tumor residue
Epstein–Barr virus deoxyribonucleic acid
Prognostic value
Prediction nomogram
Online Access:https://doi.org/10.1186/s12885-023-10827-0

Internet

https://doi.org/10.1186/s12885-023-10827-0

Similar Items